The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena. Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema. Given its success in cardiology, it is a promising...
This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis. Blepharitis is a large problem affecting many patients. This could be a large market opportunity.
Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing. A 10% reduction in intraocular pressure is not enough to make a clinical...
The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration. Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy. If CATT confirms this, it sink Lucentis Sales...
Contacts can successfully be worn with pediatric patinets as early as 10 years of age. With that being said, patient selection is crucial. You may encounter 10 year old patients that are as responsible as 7 year olds and vice versa.
Biovitrum may have discovered a new adjunct to our existing prostaglandin analogs. Currently, the prostaglandins generally lower patients pressures by 30-40% therefore making them first line therapy. If this new 5-HT2A drug can lower pressure an additional 10%, this drug would find a home...
A recent study showed that children aged 8-12 were just as successful as teenagers aged 13-17 in the areas of physiological adjustment and contact lens care. I find this is true in my practice as well. Not only can prescribing to this younger demographic change a child's life, it can...
The recent purchase by Bausch & Lomb of Eyeonics shows a good move to capture the growing presbyopic correction market. The company has also sent Ronald L. Zarrella to become chairman emeritus. One of the best moves I have heard since the whole Renu problem.
Macular degeneration is a condition where the central part of the retina is lost. This item places an image on the retina that is so big, it allows the use of the remaining, useful retina. Sounds great! It may be, however, as with many low vision devices, there are some potential pitfalls.